You are here

Novartis

Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies

Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies

Endpoints

Flag link:

Novartis pads case for new MS blockbuster with disease-progression analysis

Novartis pads case for new MS blockbuster with disease-progression analysis

Fierce Pharma

multiple sclerois

Flag link:

Good news, Glaxo: Novartis' Advair copy definitely won't see the market this year

Good news, Glaxo: Novartis' Advair copy definitely won't see the market this year

Fierce Pharma

Flag link:

[video]Did Novartis Overpay for AveXis?

[video]Did Novartis Overpay for AveXis?

Motley Fool

Flag link:

Q1 kicks off with J&J, Novartis, Glaxo results

Q1 kicks off with J&J, Novartis, Glaxo results

Biopharma Dive

Flag link:

3 Biotech Stocks That Soared This Week

3 Biotech Stocks That Soared This Week

Motley Fool

Abeona Therapeutics

Spectrum Pharmaceuticals

Flag link:

Novartis CEO: How To Create Cheaper Alternatives To The Most Expensive Drugs

Novartis CEO: How To Create Cheaper Alternatives To The Most Expensive Drugs

Forbes

Vasant Narasimham

Flag link:

Novartis offloads failed cancer drug to Oncology Venture

Novartis offloads failed cancer drug to Oncology Venture

Fierce Biotech

Oncology Venture

Flag link:

Physician payments linked to scripts for cancer drugs from Novartis, Pfizer and more: study

Physician payments linked to scripts for cancer drugs from Novartis, Pfizer and more: study

Fierce Pharma

physician payments

Bristol-Myers Squibb

Flag link:

Why Did Novartis Spend $9 Billion On Gene Therapy? CEO Says: 'A Journey To Focus On Data And Digital'

Why Did Novartis Spend $9 Billion On Gene Therapy? CEO Says: 'A Journey To Focus On Data And Digital'

Forbes

Flag link:

Biogen faces increased 'pressure' after AveXis buyout by Novartis

Biogen faces increased 'pressure' after AveXis buyout by Novartis

Marketwatch

Flag link:

Novartis buying AveXis for $8.7 billion to strengthen gene therapy capabilities

Novartis buying AveXis for $8.7 billion to strengthen gene therapy capabilities

Stat

spinal muscular atrophy

Flag link:

Novartis, still embroiled in Greek probe, faces kickback allegation in China—again

Novartis, still embroiled in Greek probe, faces kickback allegation in China—again

Fierce Pharma

Flag link:

Conatus Pharma’s Liver Disease Drug Flunks First Phase 2 Test

Conatus Pharma’s Liver Disease Drug Flunks First Phase 2 Test

Xconomy

Conatus Pharmaceuticals

clinical trials

Flag link:

Novartis Likely Delayed In Launching Copycat Of Amgen Blockbuster

Novartis Likely Delayed In Launching Copycat Of Amgen Blockbuster

Investors Business Daily

Flag link:

Novartis sues Regeneron over manufacturing methods

Novartis sues Regeneron over manufacturing methods

Biopharma Dive

drug manufacturing

Flag link:

GSK buys out Novartis in $13 billion consumer healthcare shake-up

GSK buys out Novartis in $13 billion consumer healthcare shake-up

Yahoo/Reuters

consumer healthcare

Flag link:

Pharma's social media strategies are growing up—and working better, too, report finds

Pharma's social media strategies are growing up—and working better, too, report finds

Fierce Pharma

Boehringer Ingelheim

Flag link:

Novartis' Siponimod significantly improved outcomes in PhIII data published in Lancet

Novartis' Siponimod significantly improved outcomes in PhIII data published in Lancet

CP Wire

clinical trials

multiple sclerosis

Flag link:

Pages